


## PI3K/mTOR Inhibitor-2

<b>Cat. No.:</b>	HY-111508		
<b>CAS No.:</b>	1848242-58-9		
<b>Molecular Formula:</b>	C <sub>20</sub> H <sub>13</sub> ClF <sub>2</sub> N <sub>4</sub> O <sub>4</sub> S		
<b>Molecular Weight:</b>	478.86		
<b>Target:</b>	PI3K; mTOR		
<b>Pathway:</b>	PI3K/Akt/mTOR		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 8.33 mg/mL (17.40 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.0883 mL	10.4415 mL	20.8829 mL
5 mM	0.4177 mL	2.0883 mL	4.1766 mL
10 mM	0.2088 mL	1.0441 mL	2.0883 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

PI3K/mTOR Inhibitor-2 is a potent dual pan-PI3K/mTOR inhibitor with IC<sub>50</sub>s of 3.4/34/16/1 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ and 4.7 nM for mTOR<sup>[1]</sup>. Antitumor activity<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

PI3Kα	PI3Kβ	PI3Kδ	PI3Kγ
3.4 nM (IC <sub>50</sub> )	34 nM (IC <sub>50</sub> )	16 nM (IC <sub>50</sub> )	1 nM (IC <sub>50</sub> )
mTOR			
4.7 nM (IC <sub>50</sub> )			

#### In Vitro

PI3K/mTOR Inhibitor-2 (Compound 31) inhibits p-AKT and p-p70s6k in MCF-7 cells with IC<sub>50</sub>s of 11.6 and 89.2 nM, respectively<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### CUSTOMER VALIDATION

- 
- 
- Sci Rep. 2022 Apr 12;12(1):6090.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

[1]. Yu T, et al. Discovery of Pyridopyrimidinones as Potent and Orally Active Dual Inhibitors of PI3K/mTOR. ACS Med Chem Lett. 2018 Feb 27;9(3):256-261.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA